Mount Sinai Women's Health Symposium

Wednesday, May 8, 2024, 7:00 AM - 5:15 PM, Davis Auditorium, New York, NY


This is a one-day event on women's health topics and innovations in research. The symposium will feature key speakers who are leaders in women's health.

1. To summarize the many disorders that specifically impact women at different points in their lifetime.
2. To understand the most up to date science and innovation for many common female-specific disorders just as preeclampsia, menopause, endometriosis and female-specific cancers.
3. To describe the cutting-edge research focused on improving cardiovascular, brain and overall health for women across their lifespan.

NO REGISTRATION FEE until 3/31/24

Starting 4/1/24
Physicians - $50
Allied Health Professionals, RNs, NPs, PAs - $25
Students, Residents, Fellows – No Charge
Others – No Charge

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (7.00 hours), Non-Physician Attendance (7.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

Icahn School of Medicine at Mount Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Wednesday, May 8, 2024